Ignite Creation Date:
2024-05-05 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00187512
Status:
RECRUITING
Last Update Posted:
2024-06-18
First Post:
2005-09-13
Brief Title:
SCOPE Observational Study of the Consequences of the Protease Inhibitor Era
Sponsor:
University of California San Francisco
Organization:
University of California San Francisco
Study Overview
Official Title:
SCOPE Observational Study of the Consequences of the Protease Inhibitor Era
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SCOPE
Brief Summary:
SCOPE is an observational prospective study of HIV-1 infected volunteers designed to provide a specimen bank of samples with carefully characterized clinical data SCOPE specimens will be used to examine multiple questions involving virologic immunologic and host factors involved in HIV-1 infection progression non-progression response to treatment control of HIV-1 virus and evolution of drug resistance
Detailed Description:
SCOPE is an observational prospective study of HIV-1 infected volunteers designed to provide a specimen bank of samples with carefully characterized clinical data Samples from SCOPE will be used to examine
1 Virologic immunologic and host factors involved in the natural control of HIV-1 infection long term non-progression andor virologic control of HIV-1 without antiretroviral therapy
2 Virologic and immune correlates associated with disease progression
3 Evolution of antiretroviral drug resistance
4 Factors associated with transmission or acquisition of HIV infection
Enrolled subjects are seen at San Francisco General Hospital every four months for a detailed interview saliva collection and blood draw Baseline visits take approximately one hour follow up visits take approximately 20-40 minutes No personal identifiers are used for specimen bank samples
1 Virologic immunologic and host factors involved in the natural control of HIV-1 infection long term non-progression andor virologic control of HIV-1 without antiretroviral therapy
2 Virologic and immune correlates associated with disease progression
3 Evolution of antiretroviral drug resistance
4 Factors associated with transmission or acquisition of HIV infection
Enrolled subjects are seen at San Francisco General Hospital every four months for a detailed interview saliva collection and blood draw Baseline visits take approximately one hour follow up visits take approximately 20-40 minutes No personal identifiers are used for specimen bank samples
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None